Go to the list of all blogs
published in Blogs
Jun 08, 2026
HIVE Digital Technologies (HIVE) Stock Climbs +28% Over 30 Days on Crypto Momentum

HIVE Digital Technologies (HIVE) Stock Climbs +28% Over 30 Days on Crypto Momentum

Key Takeaways

  • HIVE Digital Technologies Ltd. (HIVE) stock rose approximately 28% over the past 30 days, driven primarily by broader cryptocurrency market strength and company-specific operational expansions.
  • Over the past quarter, the stock advanced more substantially amid sustained Bitcoin price recovery and HIVE's capacity growth in mining and high-performance computing.
  • Record fiscal 2026 revenue growth of 158%, fueled by a 104% increase in Bitcoin mined and expansion into AI-related compute hosting, supported investor sentiment.
  • Recent earnings highlighted strong revenue but included a quarterly loss and revenue miss relative to some estimates, contributing to short-term volatility.
  • Sector tailwinds from rising Bitcoin prices and demand for green energy-powered data centers aligned with HIVE's business model of mining digital currencies and providing computational infrastructure.

Company Overview: HIVE Digital Technologies Ltd. (HIVE) Market Position

HIVE Digital Technologies Ltd. operates as a technology company focused on building and running data centers powered by renewable energy. Its core business involves Bitcoin mining and the sale of digital currencies, alongside performance computing hosting for blockchain networks. The company maintains facilities in locations including Canada, Paraguay, Sweden, and Bermuda, emphasizing sustainable energy sources. This positioning in the cryptocurrency mining and emerging high-performance computing sectors exposes the stock to Bitcoin price fluctuations and growing demand for AI-adjacent infrastructure, directly influencing recent price movements through operational scaling and revenue expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, HIVE stock increased approximately 28%, reflecting a generally upward trend with periods of volatility tied to cryptocurrency market swings. The movement appeared trend-driven, supported by positive sector momentum rather than purely range-bound trading.

Over the past quarter, the stock posted a larger gain of roughly 80%, consistent with a sustained recovery phase. This period showed stronger cumulative upward momentum amid improving macroeconomic conditions for digital assets and company-level capacity additions.

What Drove the +28% Gain in the Last 30 Days

The primary catalyst was the broader rally in Bitcoin and digital assets, which boosted mining revenues and investor appetite for crypto-related equities. HIVE reported record fiscal 2026 results, including a 158% revenue increase and a four-fold rise in operational hashrate, underscoring successful expansion. The company highlighted its pivot toward AI and high-performance computing using existing green-energy infrastructure, attracting attention from growth-oriented investors. While a recent quarterly earnings release noted a net loss and a revenue figure below some analyst expectations, the overall revenue surge and Bitcoin production growth (2,885 BTC mined for the year, up 104%) helped offset negative reactions and sustain the upward price trajectory.

Drivers Behind the Stronger Quarterly Advance

Over the quarter, sustained Bitcoin price appreciation and HIVE's aggressive capacity expansion formed the dominant narrative. The company achieved significant hashrate growth through acquisitions and energization of new facilities, outpacing network difficulty increases. Macroeconomic factors, including favorable conditions for risk assets and institutional interest in cryptocurrency infrastructure, amplified gains. HIVE's strategic positioning to repurpose mining facilities for AI workloads added a longer-term growth angle, encouraging sustained buying interest despite typical sector volatility. Institutional flows and positive sentiment around green mining operations contributed to the stronger cumulative advance compared to the shorter-term period.

AI Tools in My Research Process

As part of my ongoing analysis, I frequently turn to AI Trading Bots and the AI Trend Prediction Engine to gauge how stocks like HIVE might behave under different market scenarios. These resources help put price action into context alongside broader sector trends without replacing traditional fundamental review.

What Investors Should Watch Next for HIVE Stock

Investors should monitor upcoming quarterly earnings releases for updates on Bitcoin production volumes, revenue from mining operations, and progress on AI/high-performance computing initiatives. Key factors include ongoing changes in Bitcoin prices and network difficulty, regulatory developments affecting cryptocurrency mining, and macroeconomic conditions such as interest rates and risk-asset sentiment. Strategic moves like facility expansions, energy cost management, or new partnerships in data center hosting could also influence sentiment. Potential risks involve Bitcoin price corrections or increased competition in the mining sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HIVE

HIVE's Stochastic Oscillator is sitting in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HIVE's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HIVE just turned positive on August 12, 2026. Looking at past instances where HIVE's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

HIVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIVE as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HIVE entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIVE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.746) is normal, around the industry mean (4.320). P/E Ratio (9.174) is within average values for comparable stocks, (21.447). HIVE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.685). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (2.001) is also within normal values, averaging (31.286).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13.21B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was 2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was -9%. CD experienced the highest price growth at 49%, while NCPL experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was -18% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 68
Price Growth Rating: 61
SMR Rating: 76
Profit Risk Rating: 85
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
HIVE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of cloud networking and enterprise Wi-Fi solution

Industry InvestmentBanksBrokers

Profile
Details
Industry
Computer Communications
Address
7900 Callaghan Road
Phone
N/A
Employees
24
Web
https://www.hivedigitaltechnologies.com
Interact to see
Advertisement
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ÂĄ1.81 trillion, up 3.7% YoY, on track for its full-year target of ÂĄ2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
CME Group delivered record 2025 revenue of $6.52 billion, up 6% year-over-year. Q4 adjusted EPS of $2.77 exceeded expectations.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.